Experimental drug cocktail aims to tame deadly transplant complication

NCT ID NCT06996119

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether adding the drug emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity stem cell transplant. Emapalumab blocks a protein that triggers immune attacks, potentially reducing the risk of donor cells attacking the patient's body. The study focuses on safety and side effects, not yet on long-term effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emapalumab
What this could lead to: If successful, this could lead to a safer way to prevent graft-versus-host disease after stem cell transplants, improving outcomes for leukemia patients.
What could go wrong: This is a very early phase 1 trial with only 15 participants, so results may not apply broadly. The drug combination could cause serious side effects or fail to prevent GVHD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA GRAFT-VERSUS-HOST DISEASE MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.